afb3a19359
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
- Source: inbox/queue/2026-04-29-lilly-employer-connect-not-revolutionary-dte-limits.md - Domain: health - Claims: 0, Entities: 0 - Enrichments: 3 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
76 lines
7.1 KiB
Markdown
76 lines
7.1 KiB
Markdown
---
|
|
type: claim
|
|
domain: health
|
|
description: Lilly Employer Connect and Novo Nordisk DTE channels at $449/dose vs $1,000+ retail create new distribution pathway outside PBM control
|
|
confidence: experimental
|
|
source: Eli Lilly Employer Connect March 5 2026, Novo Nordisk Waltz/9amHealth January 1 2026, on/healthcare.tech analysis
|
|
created: 2026-04-28
|
|
title: Manufacturer direct-to-employer GLP-1 channels launched 2026 represent structural challenge to PBM intermediation by offering 55-60 percent price compression while bypassing traditional pharmacy benefit architecture
|
|
agent: vida
|
|
sourced_from: health/2026-04-28-glp1-managed-access-operating-systems-payer-infrastructure.md
|
|
scope: structural
|
|
sourcer: on/healthcare.tech
|
|
challenges: ["glp1-managed-access-operating-systems-require-multi-layer-infrastructure-beyond-formulary", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035"]
|
|
related: ["glp1-managed-access-operating-systems-require-multi-layer-infrastructure-beyond-formulary", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035", "manufacturer-direct-to-employer-channels-challenge-pbm-intermediation-through-price-compression"]
|
|
---
|
|
|
|
# Manufacturer direct-to-employer GLP-1 channels launched 2026 represent structural challenge to PBM intermediation by offering 55-60 percent price compression while bypassing traditional pharmacy benefit architecture
|
|
|
|
Eli Lilly launched Employer Connect on March 5, 2026, offering Zepbound at $449/dose directly to employers — a 55-60% discount versus $1,000+ retail pricing. The program operates through 15+ program administrator partnerships including GoodRx, Teladoc, Calibrate, Form Health, and Waltz, completely bypassing PBM intermediation. Novo Nordisk launched parallel direct-to-employer channels on January 1, 2026, via Waltz Health and 9amHealth partnerships.
|
|
|
|
This represents a structural challenge to the traditional pharmacy benefit architecture where PBMs control formulary access, negotiate rebates, and manage utilization. By going direct to employers, manufacturers:
|
|
|
|
1. **Eliminate PBM margin**: The $449 price point suggests manufacturers are willing to sacrifice margin to establish direct relationships
|
|
2. **Control the access infrastructure**: Program administrators (Calibrate, Form Health, Waltz) provide the behavioral support and utilization management that PBMs were building
|
|
3. **Capture the employer relationship**: Direct contracting positions manufacturers as benefit design partners, not just drug suppliers
|
|
|
|
The timing is significant: these channels launched in Q1 2026, exactly when PBMs (Evernorth, Optum Rx) were building their own managed-access infrastructure. This suggests manufacturers recognized the strategic risk of PBMs controlling the access layer and moved to disintermediate.
|
|
|
|
The durability of this model is uncertain (hence experimental confidence). Questions remain:
|
|
- Can manufacturers sustain $449 pricing at scale?
|
|
- Will employers accept the administrative complexity of direct contracting?
|
|
- How will PBMs respond — price matching, exclusion, or regulatory challenge?
|
|
|
|
But the structural challenge is real: if manufacturers can profitably deliver GLP-1s at 55-60% below retail while providing behavioral support infrastructure, the PBM value proposition in this category is threatened.
|
|
|
|
|
|
## Extending Evidence
|
|
|
|
**Source:** PHTI December 2025 employer report
|
|
|
|
Eli Lilly Employer Connect launched March 5, 2026 at $449/dose with partnerships across 15+ program administrators (GoodRx, Teladoc, Calibrate, Form Health, Waltz). Novo Nordisk launched parallel DTE with Waltz Health and 9amHealth on January 1, 2026. Both manufacturers are bundling behavioral support infrastructure into the DTE channel, not just offering price compression.
|
|
|
|
|
|
## Supporting Evidence
|
|
|
|
**Source:** HR Brew/PR Newswire Q4 2025-Q1 2026 DTE announcements
|
|
|
|
Both major GLP-1 manufacturers (Eli Lilly via Employer Connect, Novo Nordisk via 9amHealth/Waltz Health partnerships) now operate DTE channels as of Q1 2026. Novo's Waltz Health DTE program launched January 1, 2026 for FDA-approved obesity medications. 9amHealth's No-Barriers Bundle integrates access to medications from both manufacturers at fixed monthly costs. However, neither manufacturer has disclosed enrollment data or market penetration, and expert consensus characterizes DTE as 'manufacturers positioning themselves as more active participants in employer access strategy' rather than structural displacement of PBM intermediation.
|
|
|
|
|
|
## Challenging Evidence
|
|
|
|
**Source:** MedCity News / National Alliance expert assessment, March 2026
|
|
|
|
Lilly Employer Connect's $449/month net price for Zepbound 'doesn't appear to be substantially lower than the price employers were already getting' through existing PBM channels according to National Alliance of Healthcare Purchaser Coalitions expert. Big Three PBMs (CVS Caremark, OptumRx, Express Scripts) still control approximately 80% of US prescription claims. The DTE channel represents a 'governance shift rather than structural disruption' per Sequoia analysis - manufacturers becoming direct participants in employer benefit design rather than achieving price disruption.
|
|
|
|
|
|
## Extending Evidence
|
|
|
|
**Source:** HR Brew/PR Newswire Q1 2026 DTE program launches
|
|
|
|
Both Novo Nordisk (via 9amHealth No-Barriers Bundle and Waltz Health DTE program, launched January 1, 2026) and Eli Lilly now operate DTE channels. 9amHealth integrates access to FDA-approved obesity medications from BOTH manufacturers at fixed monthly costs, creating a multi-manufacturer DTE platform. However, expert consensus characterizes this as 'incremental governance shift, not structural PBM displacement' and 'manufacturers positioning themselves as more active participants in employer access strategy' rather than true intermediation disruption. Neither manufacturer has disclosed enrollment data or market penetration.
|
|
|
|
|
|
## Supporting Evidence
|
|
|
|
**Source:** Medical Economics, November 2025
|
|
|
|
Cost Plus Drugs' partnership with Humana for 'end-to-end employer prescription solutions' represents another direct-to-employer channel that bypasses traditional PBM spread pricing through transparent cost-plus-15% pricing. However, the fact that Cost Plus chose to partner with Humana's CenterWell Pharmacy rather than build independent distribution infrastructure suggests that direct channels still require incumbent partnerships for scale, limiting the disintermediation potential.
|
|
|
|
|
|
## Challenging Evidence
|
|
|
|
**Source:** MedCity News / National Alliance expert assessment, March 2026
|
|
|
|
Lilly Employer Connect's $449/month net price for Zepbound 'doesn't appear to be substantially lower than the price employers were already getting' through existing PBM channels according to National Alliance of Healthcare Purchaser Coalitions expert. Big Three PBMs (CVS Caremark, OptumRx, Express Scripts) still control approximately 80% of US prescription claims. The DTE channel represents a governance shift (manufacturers as direct participants in employer benefit design) rather than price disruption.
|